Michael P Buchanio

Background

Michael is a Managing Director within the KPMG Deal Advisory and Strategy guiding private equity and strategic buyers through all stages of the M&A lifecycle, assessing acquisition targets, managing cross-functional diligence, separation and integration efforts, and leading multi-disciplinary initiatives to identify and deliver value within their portfolio.

Michael has over 20 years of experience as an advisor across private equity, drug development, healthcare provider, medical device, DTP retail, lab/diagnostics, pharmacy and payer/PBM; with deep expertise in emerging technologies, business models, and advanced analytics and clinical data hubs. At the intersection of technology and operations, he helps investors understand and improve key systems and processes by identifying gaps and informing plans to de-risk, differentiate, enhance, and scale. More specifically, due to Michael's deal work, he has a breadth of experience, both operationally and functionally with the majority of leading healthcare technologies including recent advancements in traditional and generative artificial intelligence. This exposure required Michael to assess current solutions and compare capabilities and potential fit of competitor solutions and provide recommendations.

Prior to KPMG, Michael was a Senior Principal at West Monroe where he led its healthcare and life sciences M&A practice which oversaw more than 150 healthcare and life sciences transactions and 50 post-close engagements. Previously, he was a senior healthcare attorney representing large health systems and pharmaceutical companies in various regulatory and transactional matters including over 50+ 340B audits.

Select Professional and Industry Experience

• Growth strategy, technical and operational performance improvement of a global clinical research and RWE organization; assessed functional capabilities of proprietary solutions versus those of key competitors. Led synergy analysis, integration strategy, planning and management of 8+ additional platform acquisitions.
• Led separation diligence including stand-alone cost, TSA development and pre-close planning for $3B post-acute home health and hospice provider. Followed by a synergy assessment and integration planning for a $1B hospice acquisition.
• Led the operational and technology diligence, carve-out and merger activities of a national $13B post-acute care focused pharmacy and PBM including multiple unique and proprietary pharmacy management system migrations. Developed best of breed strategy for future state enterprise architecture and roadmap for performance improvement.
• Clinical trial and patient engagement optimization for pharmaceutical company to incorporate more patient centric, decentralized trials features and functionality to improve data collection, speed, an overall patient experience and retention; leveraged our data analytics to significantly accelerate site selection, patient recruitment and diversity.
• Growth strategy for a global life sciences and diagnostic innovator exploring inorganic platform expansion into healthcare technology; evaluated HCIT markets and specific Targets for acquisition including competitive benchmarking, new product launch assessments, and GenAI impact.
• Led the diligence and performance improvement of a $8B clinical research organization including developing a M&A target pipeline and playbook for their corporate development team. Developed a technology roadmap to revamp clinical trial solutions and services including AI/ML clinical data hubs to accelerate data ingestion and querying.
• Growth strategy and operational assessment and future state modeling for contract device and drug manufacturing organizations including performance improvement impact; led value capture execution and integration of recent acquisitions.
• Developed and executed organic and inorganic growth strategies including actionable M&A and De Novo playbooks for national leading multi-specialty providers, behavioral health, and physical therapy organizations.
• Developed and executed a digital transformation strategy roadmap and M&A playbook for national health organization after an aggressive acquisitive growth period including an end-to-end value chain diagnostic to identify barriers to information flow, make lasting and meaningful improvements, and drive a 240% EBITDA improvement.